Boston Biomedical, Inc. (BBI) - Columbia University Collaboration

Columbia is pleased to announce the 2019 Request for Short Proposals under the strategic research alliance between Columbia University and Boston Biomedical, Inc. (BBI) a subsidiary of Sumitomo Pharma.

Submit a PDF short proposal HERE by Wednesday, December 4th at 11:59PM.

This strategic research alliance is a collaboration to advance research toward the development of disruptive technology platforms, novel science, and IND ready molecule(s) in the field of ONCOLOGY.

Topics of interest include (but are not limited to):

  • Cancer Genomics and Epigenomics
  • Tumor biology and microenvironment
  • Precision Oncology and Systems Biology
  • Cancer Population Science
  • Cancer cell metabolism
  • Immune-oncology and immunotherapy
  • Gene and cell therapy
  • DNA vaccines and therapy
  • Microbiome
  • RNAi and oncolytic viruses
  • Drug delivery systems
  • Gene editing
  • Mechanisms of anti-aging therapy
  • Organ-on-a-chip
  • Imaging and radio-omics

Applicants must have a full-time Columbia University faculty appointment and should prepare a 3-page non-confidential short proposal using the Boston Biomedical – Columbia University RFP proposal submission template.

Questions? Please contact